Navigation Links
Former FDA Commissioner Joins Bexion Pharmaceuticals Board

COVINGTON, Ky., Jan. 6, 2011 /PRNewswire/ -- Bexion Pharmaceuticals, LLC announced today that it has added Lester Crawford, D.V.M., and Ph.D. to its Board of Directors.

Dr. Crawford has had a distinguished career in the public and private sectors as well as academia. Over ten years of his career were spent at the Food and Drug Administration (FDA) serving in a variety of pivotal roles and culminating in his appointment as FDA Commissioner.

Prior to FDA, Dr. Crawford served in many capacities at the University of Georgia, including chair of the Department of Physiology and Pharmacology and at Georgetown University where he was director of the Center for Food and Nutrition Policy. Dr. Crawford has been an expert advisor to the World Health Organization, the Singapore FDA and the U. S. Academy of Sciences. He is currently a Partner and Senior Science Advisor at Policy Directions, Inc.

"We are excited and privileged to have Dr. Crawford join our Board of Directors," stated Dr. Ray Takigiku, Bexion's co-founder and CEO. "Dr. Crawford brings us important insights on regulatory and industry issues that are vital as we approach an IND submission in 2011, and anticipated clinical trials", added Dr. Takigiku.

"I am especially pleased to join Bexion's Board of Directors," added Dr. Crawford. "I am looking forward to sharing my experience over a long career to help Bexion reach its goal of providing first-in-class, innovative technology to cancer patients worldwide."

About Bexion Pharmaceuticals:Bexion Pharmaceuticals is focused on the development and commercialization of innovative cures for cancer.  Initial products are based on a proprietary platform technology licensed from Cincinnati Children's Hospital Medical Center.  The technology has demonstrated potential for development as therapeutic, diagnostic and surgical imaging reagents, and as carriers for other pharmaceutical agents, such as oligonucleotides.  For more information, visit contact:Margaret M. van GilseVP, Investor RelationsBexion Pharmaceuticals, LLC632 Russell StreetCovington, KY 41011Phone: (513)

SOURCE Bexion Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Michigan Life Science and Innovation Center Opens in Former Pfizer Facility
6. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
7. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
8. Former Miss USA Shawnae Jebbia Shines with Siemens Pure
9. Secure eHealth, LLC Engages as a Consultant GSI Health Whose Principal and CEO is the Former Senior Advisor to National Coordinator for Health Information Technology
10. Former Air Force Surgeon General Joins Integrated Medical Systems Advisory Board
11. SCAI Statement on the Hospitalization of Former President Bill Clinton
Post Your Comments:
(Date:12/1/2015)... Calif. , Dec. 1, 2015 ... products and services, announced today that it has been ... services organization. Members served by Novation will have access ... devices, sports bracing products and soft goods dedicated to ... --> The aging U.S. population, rising prevalence ...
(Date:12/1/2015)... 2015 Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country of ... registered in Europe in 2015 were tested in ... Russia has always been a country of choice for ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation ... utilization of hospital and nonhospital care, according to a recent study by the Workers ... 16th Edition , found medical payments per claim with more than seven days of ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is ... a number even greater among Millennials (a whopping one in three aged 18 to ... people who are dissatisfied with their ink. In fact, RealSelf , the world’s ...
(Date:12/1/2015)... ... 01, 2015 , ... For many X-rays taken at hospitals, ... interpretation by the radiologist. The marking utensils are so small, however, they are ... a way to alleviate this problem. , He developed the patent-pending MARK N ...
(Date:12/1/2015)... ... 01, 2015 , ... Next IT Healthcare, the leader in ... this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher ... in the category of Digital Solutions for its innovative, industry-leading product, Alme Health ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
Breaking Medicine News(10 mins):